Novartis AG
NVSEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -6.34 | 1.10 | 0.51 | -1.67 |
| FCF Yield | 2.38% | 2.61% | 1.57% | 1.60% |
| EV / EBITDA | 45.05 | 42.75 | 41.27 | 40.62 |
| Quality | ||||
| ROIC | 5.07% | 5.32% | 5.00% | 3.70% |
| Gross Margin | 75.35% | 77.61% | 76.31% | 75.48% |
| Cash Conversion Ratio | 1.67 | 1.66 | 1.01 | 1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.52% | 1.31% | 0.45% | -0.68% |
| Free Cash Flow Growth | -5.99% | 80.06% | 10.74% | -44.20% |
| Safety | ||||
| Net Debt / EBITDA | 3.85 | 4.28 | 4.15 | 3.82 |
| Interest Coverage | 16.02 | 16.17 | 16.97 | 12.84 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.53 | 0.55 | 0.58 |
| Cash Conversion Cycle | 103.77 | 104.46 | 101.33 | 94.15 |